Weekly Digest – December 2024 Weekly Digest – December 2024 10 Dec 2024: NextCure announces acceptance of IND application for LNCB74 NextCure announced that the FDA accepted its Investigational New Drug (IND) application for LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC) […]
Weekly Digest – December 2024 Weekly Digest – December 2024 09 Dec 2024: Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer Datopotamab deruxtecan (Dato-DXd) has received Breakthrough Therapy Designation […]
Weekly Digest – December 2024 Weekly Digest – December 2024 09 Dec 2024: Blenrep (belantamab mafodotin) combination accepted for priority review in China in relapsed/refractory multiple myeloma The National Medical Products Administration (NMPA) of China has accepted a new drug […]
Weekly Digest – December 2024 Weekly Digest – December 2024 04 Dec 2024: Henlius receives IND approval from NMPA for a phase 1b/2 clinical trial of its novel PD-L1-targeting ADC HLX43 Shanghai Henlius Biotech’s HLX43, a PD-L1-targeting antibody-drug conjugate (ADC), […]
Weekly Digest – December 2024 Weekly Digest – December 2024 03 Dec 204: FDA grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for the treatment of certain patients with previously treated advanced or metastatic nonsquamous non-small cell lung cancer with […]
Weekly Digest – December 2024 Weekly Digest – December 2024 04 Dec 2024: GSK goes East again, snagging option on preclinical DualityBio ADC for $30M GSK has entered into a deal with Duality Biologics to license a preclinical antibody-drug conjugate […]
Weekly Digest – December 2024 Weekly Digest – December 2024 04 Dec 2024: GSK goes East again, snagging option on preclinical DualityBio ADC for $30M GSK has entered into a deal with Duality Biologics to license a preclinical antibody-drug conjugate […]
Weekly Digest – November 2024 Weekly Digest – November 2024 25 Nov 2024: Adcendo raises $135m as ADC funding frenzy continues Adcendo raised $135 million in funding to advance its portfolio of first-in-class ADCs into clinical trials Company’s ADC candidate, […]
Weekly Digest – November 2024 Weekly Digest – November 2024 25 Nov 2024: Adcendo raises $135m as ADC funding frenzy continues Adcendo raised $135 million in funding to advance its portfolio of first-in-class ADCs into clinical trials Company’s ADC candidate, […]
Weekly Digest – November 2024 Weekly Digest – November 2024 28 Nov 2024: Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline Allink Biotherapeutics has successfully raised $42 million in a Series […]
